Metraipolis › archive › dc_533cf6eaf1ba

Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring — Europe PMC PMID:35192655

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/35192655
DOI
10.1371/journal.pone.0263664
License (as archived)
CC0-1.0
Archived
2026-10-31T09:13:40.346Z
SHA-256 of the archived text
1a8c57e815cc2a52c29789fb4b00a68edc82f678273072d313d61704db01467b
Stable URL of this page
https://metraipolis.com/documento/dc_533cf6eaf1ba

How to cite

Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring — Europe PMC PMID:35192655 — Europe PMC (en), https://europepmc.org/article/MED/35192655 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_533cf6eaf1ba (Metraipolis archive dc_533cf6eaf1ba, sha256 1a8c57e815cc2a52c29789fb4b00a68edc82f678273072d313d61704db01467b)
BibTeX
@misc{dc533cf6eaf1ba,
  title = {Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring — Europe PMC PMID:35192655},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/35192655},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_533cf6eaf1ba; sha256 1a8c57e815cc2a52c29789fb4b00a68edc82f678273072d313d61704db01467b},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35192655. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Given challenges with adherence to existing HIV prevention products, the development of an extended duration vaginal ring could improve adherence while reducing patient and provider burden. Additionally, women have other interlinked sexual health concerns such as unintended pregnancy. We evaluated acceptability of a 90-day ring to prevent HIV and hypothetical preferences for a dual (HIV and contraceptive) indication. This was a secondary analysis of a Phase 1, two-arm, multi-site, placebo-controlled randomized trial evaluating safety and pharmacokinetics of a 90-day vaginal ring containing tenofovir for HIV prevention (N = 49). We used a mixed methods approach to assess quantitative data on acceptability (n = 49) and used qualitative data from a random subset to explain the quantitative findings (N = 25). The 3-month extended duration tenofovir ring was highly acceptable. Participants perceived the ring to be easy to use, comfortable and reported liking it more over time. About half felt the ring during sex but most of those participants said it bothered them only a little. Concerns about hygiene increased over the study period but were often outweighed by the benefits of an extended duration ring. Interest in a multi-purpose ring was high (77%) and even higher among those who were sexually active and had male partners. The 3-month extended duration tenofovir ring for HIV prevention was highly acceptable among women and interest in an MPT was high.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-02-22).
Identificativi: PMID 35192655 · PMCID PMC8863232 · DOI 10.1371/journal.pone.0263664.
Descrittori MeSH principali: Contraceptive Devices, Female.
Pagina: https://europepmc.org/article/MED/35192655 — https://doi.org/10.1371/journal.pone.0263664. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-31T09:01:45.956Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.